U.S. markets closed
  • S&P Futures

    3,249.75
    +11.75 (+0.36%)
     
  • Dow Futures

    26,808.00
    +93.00 (+0.35%)
     
  • Nasdaq Futures

    10,939.00
    +47.25 (+0.43%)
     
  • Russell 2000 Futures

    1,456.60
    +9.60 (+0.66%)
     
  • Crude Oil

    40.28
    -0.03 (-0.07%)
     
  • Gold

    1,869.00
    -7.90 (-0.42%)
     
  • Silver

    23.16
    -0.04 (-0.18%)
     
  • EUR/USD

    1.1673
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    0.6660
    -0.0100 (-1.48%)
     
  • Vix

    28.51
    -0.07 (-0.24%)
     
  • GBP/USD

    1.2754
    +0.0002 (+0.01%)
     
  • USD/JPY

    105.4580
    +0.0560 (+0.05%)
     
  • BTC-USD

    10,733.48
    -27.11 (-0.25%)
     
  • CMC Crypto 200

    227.52
    +18.58 (+8.89%)
     
  • FTSE 100

    5,822.78
    -76.48 (-1.30%)
     
  • Nikkei 225

    23,200.83
    +113.01 (+0.49%)
     

TG Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare Conference

Presentation scheduled for, Thursday, June 11, 2020, at 4:40 PM ET

NEW YORK, June 09, 2020 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (TGTX), today announced that Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, will participate in a fireside chat during the Gladman Sachs 41st Annual Healthcare Conference, being held virtually. The fireside chat is scheduled to take place on Thursday, June 11, 2020 at 4:40 PM ET.

A live webcast of this presentation will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.


ABOUT TG THERAPEUTICS, INC.
TG Therapeutics is a biopharmaceutical company focused on the acquisition, development and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Currently, the company is developing multiple therapies targeting hematological malignancies and autoimmune diseases. Ublituximab (TG-1101) is a novel, glycoengineered monoclonal antibody that targets a specific and unique epitope on the CD20 antigen found on mature B-lymphocytes. TG Therapeutics is also developing umbralisib (TGR-1202), an oral, once-daily dual inhibitor of PI3K-delta and CK1-epsilon, which may lead to a differentiated safety profile. Both ublituximab and umbralisib, or the combination of which is referred to as "U2", are in Phase 3 clinical development for patients with hematologic malignancies, with ublituximab also in Phase 3 clinical development for Multiple Sclerosis. Additionally, the Company has recently brought into Phase 1 clinical development its anti-PD-L1 monoclonal antibody, cosibelimab (TG-1501), its covalently-bound Bruton’s Tyrosine Kinase (BTK) inhibitor, TG-1701, as well as its anti-CD47/CD19 bispecific antibody, TG-1801. TG Therapeutics is headquartered in New York City.

CONTACT:

Jenna Bosco
Senior Vice President,
Corporate Communications
TG Therapeutics, Inc.
Telephone: 212.554.4351
Email: ir@tgtxinc.com